Merck

RENFLEXIS

  1. Home
  2.  / 
  3. Q Code
  4.  / RENFLEXIS – Q5104

Manufacturer:

Merck

Name:

RENFLEXIS

HCPCS Code Descriptor:

Injection, infliximab-abda, biosimilar, (renflexis), 10 mg

Category:

Q Code

HCPCS:

Q5104

NDC(s):

78206-0162-01, 00006-4305-02

Primary Type:

Immunology Anti-TNF Biosimilar

Generic Status:

Multi-Source

Route of Administration:

Intravenous

About:

RENFLEXIS is an Immunology Anti-TNF Biosimilar drug manufactured by Merck and administered via the Intravenous route of administration. The Q Code: Q5104 is aligned to the drug RENFLEXIS.

Renflexis (infliximab) is a monoclonal antibody that is used to treat a range of inflammatory autoimmune disorders. Renflexis binds to tumor necrosis factor-alpha and hinders it from activating certain processes. This medication is administered via intravenous infusion over the course of multiple weeks. Renflexis is manufactured by Merck Sharp & Dohme and Organon and is biosimilar to Remicade (J1745). The Q Code that was assigned to this medication (Q5104) has been effective since April 2018. Patient assistance programs for this medication can be found through the Organon access program.

Access Pricing and More By Registering

HCPCS Added Date:

4/1/18

HCPCS Effective Date:

4/1/18

HCPCS Short Description:

Injection, renflexis

Billing and Coding Guide:

Not Found

Patient Assistance:

https://www.organonaccessprogram-renflexis.com/hcc/

RENFLEXIS - Q5104